To adequately compare detection power in patient biofluids, we developed and tested TERT breakpoint ddPCR on ctDNA in peripheral blood and BM plasma in parallel with genomic DNA from the cellular components in the BM aspirates and (multiregion) tumor biopsies collected at initial diagnosis or relapse from individual patients. The gene discussed is TERT; the disease is neoplasm.